Amendments to the Specification

Kindly amend the paragraph, beginning at page 4, line 25, as follows:

To compensate for the apparent lack of sufficient quantities of DPPIV and to generally rebuild proper functioning of an autistic individual's intestinal tract with regard to absorption and digestion, different approaches have been employed. Of these, enzyme therapy and probiotic supplementation have been favored and met a degree of success. ~~Enzyme therapy was developed, in part, through the pioneering work of Dr. Jon Pangborn and Dr. Bernard Rimland, working on behalf of the Autism Research Institute (ARI). These researchers recognized the need for and developed an enzyme composition that cleaves gluteppmorphins such as Gly Tyr Tyr Pro Thr and related sequences, and casomorphins such as Tyr Pro Phe Pro and related sequences (see publication entitled Peptidase Enzyme Digestive Aid Project, by Pangborn, J., published at ARI's 3rd Annual Defeat Autism Now! Conference, September 1997.~~ Enzyme therapy has typically been based on supplementation with large amounts of protease from different categories of proteolytic enzymes and these have included acid or carboxyl peptidases, peptidases with both endo- and exo-peptidase activity, and serine, cysteine and zinc proteases. More recently ~~(following the work of Pangborn and Rimland)~~, exogenic DDPIV from animal (usually cow or pig) and plant sources has been utilized ~~(see Peptidase Enzyme Digestive Aid Project, by Pangborn, J., published at the Autism Research Institute's 3rd Annual Defeat Autism Now! Conference, September 1997~~. While enzyme therapy has had limited success, it is disadvantageous, amongst other reasons, in that many proteases, including DDPIV, are ~~substantially~~ broken down in the stomach and do not reach the intestines in a functional state.

Kindly cancel the following paragraphs previously added at page 6, line 26:

~~In one embodiment the present invention includes a composition that has a physiologically effective amount of a purified genomeceutical material of the type that affects expression of a DPPIV like compounds when ingested by a human in such a manner as to relieve symptoms of autism, and one or more of a purified protease, a purified peptidase that exhibits DPPIV like activity or a purified phytase. The genomeceutical material may be galactose or glucans or other similarly functioning material. The peptidase may be DPPIV or QPP. The protease may be an acid fast~~

protease or a cystein protease. The composition may also include a purified phospholipids containing substance, a purified disaccharidase and/or a purified lipase.

In another embodiment, the present invention includes a composition that has a purified phytase like compound, and a physiologically effective amount of one or more of a purified genomeceutical for treating autism or a purified peptidase that exhibits DPPIV like activity for treating autism. This composition may also include an acid fast protease, a purified phospholipids containing material and/or a purified lipase. The genomeceutical may include at least one of purified galactose or purified glucans.

In yet another embodiment, the present invention includes a method of preparing a composition for treatment of autism that has the steps of: providing a physiologically effective amount of a purified genomeceutical material of the type that affects expression of a DPPIV like compounds when ingested by a human in such a manner as to relieve symptoms of autism; providing at least one of a purified protease, a purified peptidase that exhibits DPPIV like activity or a purified phytase; and mixing said purified genomeceutical and said one of said purified protease, peptidase or phytase to achieve a compound effective in treating symptoms of autism. The step of providing a purified genomeceutical may include the step of providing at least one of purified galactose and purified glucans, while the step of providing a purified protease may include the step of providing at least one of a purified acid fast protease and a purified cystein protease.

Kindly cancel the following paragraph previously added at page 7, line 2:

The following quoted terms and phrases are defined as follows. "Composition" refers to a combination of multiple substances into an aggregate mixture. "Purified" indicates that a substance is provided in a state that is more pure than that substances occurs in its natural state, though a "purified" substance may contain other active or inactive material. "Physiologically effective amount" refers to an amount of an active substance that is sufficient to achieve an externally observable effect on a patient.